Is omalizumab safe and effective in oncological patients?

A 42‐year‐old female with a personal history of Grade II infiltrating ductal breast carcinoma, treated under surgical procedure in 2018, whose hormonal profile included estrogen, progesteronic and HER‐2 positive receptors, and a Ki67 proliferative index (20–25%), was referred to our dermatological o...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Dermatologic therapy 2019-11, Vol.32 (6), p.e13115-n/a
Hauptverfasser: Navarro‐Triviño, Francisco J., Mérida‐Fernández, Carolina, Linares‐Gonzalez, Laura, Ruiz‐Villaverde, Ricardo
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page n/a
container_issue 6
container_start_page e13115
container_title Dermatologic therapy
container_volume 32
creator Navarro‐Triviño, Francisco J.
Mérida‐Fernández, Carolina
Linares‐Gonzalez, Laura
Ruiz‐Villaverde, Ricardo
description A 42‐year‐old female with a personal history of Grade II infiltrating ductal breast carcinoma, treated under surgical procedure in 2018, whose hormonal profile included estrogen, progesteronic and HER‐2 positive receptors, and a Ki67 proliferative index (20–25%), was referred to our dermatological outpatient clinic complaining worsening of her chronic spontaneous urticaria. The patient was under treatment with etuximide, exemestane, anastrozole, and trastuzumab. Our patient reported intermittent episodes of hives of 8 years of evolution with good control with second‐generation antihistamines. However, in the past year, the intensity and frequency of the outbreaks was increased with the development of angioedema until completing 23 consultations through the emergency department being treated in all of the episodes with short cycles of oral corticosteroids. This case reported is particularly complex due to different points that we develop below: (a) oncological patient as special population; (b) differential diagnosis with other forms of urticaria such as vasculitis urticaria, inducible urticaria, and autoimmune progesterone dermatitis; (c) spontaneous chronic urticaria of difficult control at labeled dose of omalizumab; (d) concomitant treatment with another biological drug.
doi_str_mv 10.1111/dth.13115
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2308520720</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2308520720</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3605-efe08cf8bbbe7f251fab9d32c22fca38bae29b6d084834f63f7282318665f9243</originalsourceid><addsrcrecordid>eNp1kDtPwzAURi0EoqUw8AdQRhjS-pE49oRQebRSJZYyW7ZzDUZ5ESeg8usJpLBxl-8OR2c4CJ0TPCfDLfLuZU4YIekBmpKUylhgIg-Hn0keYyr5BJ2E8IoxoZKRYzRhhCc8I3yK5DpEdakL_9mX2kRBO4h0lUfgHNjOv0Pkq6iubF3Uz97qImp056HqwvUpOnK6CHC23xl6ur_bLlfx5vFhvbzZxJZxnMbgAAvrhDEGMkdT4rSROaOWUmc1E0YDlYbnWCSCJY4zl1FBGRGcp07ShM3Q5eht2vqth9Cp0gcLRaErqPugKMMipTijeECvRtS2dQgtONW0vtTtThGsvkupoZT6KTWwF3ttb0rI_8jfNAOwGIEPX8Duf5O63a5G5Rf9XHFu</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2308520720</pqid></control><display><type>article</type><title>Is omalizumab safe and effective in oncological patients?</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Navarro‐Triviño, Francisco J. ; Mérida‐Fernández, Carolina ; Linares‐Gonzalez, Laura ; Ruiz‐Villaverde, Ricardo</creator><creatorcontrib>Navarro‐Triviño, Francisco J. ; Mérida‐Fernández, Carolina ; Linares‐Gonzalez, Laura ; Ruiz‐Villaverde, Ricardo</creatorcontrib><description>A 42‐year‐old female with a personal history of Grade II infiltrating ductal breast carcinoma, treated under surgical procedure in 2018, whose hormonal profile included estrogen, progesteronic and HER‐2 positive receptors, and a Ki67 proliferative index (20–25%), was referred to our dermatological outpatient clinic complaining worsening of her chronic spontaneous urticaria. The patient was under treatment with etuximide, exemestane, anastrozole, and trastuzumab. Our patient reported intermittent episodes of hives of 8 years of evolution with good control with second‐generation antihistamines. However, in the past year, the intensity and frequency of the outbreaks was increased with the development of angioedema until completing 23 consultations through the emergency department being treated in all of the episodes with short cycles of oral corticosteroids. This case reported is particularly complex due to different points that we develop below: (a) oncological patient as special population; (b) differential diagnosis with other forms of urticaria such as vasculitis urticaria, inducible urticaria, and autoimmune progesterone dermatitis; (c) spontaneous chronic urticaria of difficult control at labeled dose of omalizumab; (d) concomitant treatment with another biological drug.</description><identifier>ISSN: 1396-0296</identifier><identifier>EISSN: 1529-8019</identifier><identifier>DOI: 10.1111/dth.13115</identifier><identifier>PMID: 31646716</identifier><language>eng</language><publisher>Hoboken, USA: John Wiley &amp; Sons, Inc</publisher><subject>Adult ; Breast Neoplasms - drug therapy ; Carcinoma, Ductal, Breast - drug therapy ; Chronic Disease ; effectiveness ; Female ; Humans ; omalizumab ; Omalizumab - administration &amp; dosage ; Omalizumab - adverse effects ; safety ; trastuzumab ; Urticaria - drug therapy</subject><ispartof>Dermatologic therapy, 2019-11, Vol.32 (6), p.e13115-n/a</ispartof><rights>2019 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3605-efe08cf8bbbe7f251fab9d32c22fca38bae29b6d084834f63f7282318665f9243</citedby><cites>FETCH-LOGICAL-c3605-efe08cf8bbbe7f251fab9d32c22fca38bae29b6d084834f63f7282318665f9243</cites><orcidid>0000-0002-5454-3671 ; 0000-0002-0381-6174</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fdth.13115$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fdth.13115$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31646716$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Navarro‐Triviño, Francisco J.</creatorcontrib><creatorcontrib>Mérida‐Fernández, Carolina</creatorcontrib><creatorcontrib>Linares‐Gonzalez, Laura</creatorcontrib><creatorcontrib>Ruiz‐Villaverde, Ricardo</creatorcontrib><title>Is omalizumab safe and effective in oncological patients?</title><title>Dermatologic therapy</title><addtitle>Dermatol Ther</addtitle><description>A 42‐year‐old female with a personal history of Grade II infiltrating ductal breast carcinoma, treated under surgical procedure in 2018, whose hormonal profile included estrogen, progesteronic and HER‐2 positive receptors, and a Ki67 proliferative index (20–25%), was referred to our dermatological outpatient clinic complaining worsening of her chronic spontaneous urticaria. The patient was under treatment with etuximide, exemestane, anastrozole, and trastuzumab. Our patient reported intermittent episodes of hives of 8 years of evolution with good control with second‐generation antihistamines. However, in the past year, the intensity and frequency of the outbreaks was increased with the development of angioedema until completing 23 consultations through the emergency department being treated in all of the episodes with short cycles of oral corticosteroids. This case reported is particularly complex due to different points that we develop below: (a) oncological patient as special population; (b) differential diagnosis with other forms of urticaria such as vasculitis urticaria, inducible urticaria, and autoimmune progesterone dermatitis; (c) spontaneous chronic urticaria of difficult control at labeled dose of omalizumab; (d) concomitant treatment with another biological drug.</description><subject>Adult</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Carcinoma, Ductal, Breast - drug therapy</subject><subject>Chronic Disease</subject><subject>effectiveness</subject><subject>Female</subject><subject>Humans</subject><subject>omalizumab</subject><subject>Omalizumab - administration &amp; dosage</subject><subject>Omalizumab - adverse effects</subject><subject>safety</subject><subject>trastuzumab</subject><subject>Urticaria - drug therapy</subject><issn>1396-0296</issn><issn>1529-8019</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kDtPwzAURi0EoqUw8AdQRhjS-pE49oRQebRSJZYyW7ZzDUZ5ESeg8usJpLBxl-8OR2c4CJ0TPCfDLfLuZU4YIekBmpKUylhgIg-Hn0keYyr5BJ2E8IoxoZKRYzRhhCc8I3yK5DpEdakL_9mX2kRBO4h0lUfgHNjOv0Pkq6iubF3Uz97qImp056HqwvUpOnK6CHC23xl6ur_bLlfx5vFhvbzZxJZxnMbgAAvrhDEGMkdT4rSROaOWUmc1E0YDlYbnWCSCJY4zl1FBGRGcp07ShM3Q5eht2vqth9Cp0gcLRaErqPugKMMipTijeECvRtS2dQgtONW0vtTtThGsvkupoZT6KTWwF3ttb0rI_8jfNAOwGIEPX8Duf5O63a5G5Rf9XHFu</recordid><startdate>201911</startdate><enddate>201911</enddate><creator>Navarro‐Triviño, Francisco J.</creator><creator>Mérida‐Fernández, Carolina</creator><creator>Linares‐Gonzalez, Laura</creator><creator>Ruiz‐Villaverde, Ricardo</creator><general>John Wiley &amp; Sons, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-5454-3671</orcidid><orcidid>https://orcid.org/0000-0002-0381-6174</orcidid></search><sort><creationdate>201911</creationdate><title>Is omalizumab safe and effective in oncological patients?</title><author>Navarro‐Triviño, Francisco J. ; Mérida‐Fernández, Carolina ; Linares‐Gonzalez, Laura ; Ruiz‐Villaverde, Ricardo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3605-efe08cf8bbbe7f251fab9d32c22fca38bae29b6d084834f63f7282318665f9243</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adult</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Carcinoma, Ductal, Breast - drug therapy</topic><topic>Chronic Disease</topic><topic>effectiveness</topic><topic>Female</topic><topic>Humans</topic><topic>omalizumab</topic><topic>Omalizumab - administration &amp; dosage</topic><topic>Omalizumab - adverse effects</topic><topic>safety</topic><topic>trastuzumab</topic><topic>Urticaria - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Navarro‐Triviño, Francisco J.</creatorcontrib><creatorcontrib>Mérida‐Fernández, Carolina</creatorcontrib><creatorcontrib>Linares‐Gonzalez, Laura</creatorcontrib><creatorcontrib>Ruiz‐Villaverde, Ricardo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Dermatologic therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Navarro‐Triviño, Francisco J.</au><au>Mérida‐Fernández, Carolina</au><au>Linares‐Gonzalez, Laura</au><au>Ruiz‐Villaverde, Ricardo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Is omalizumab safe and effective in oncological patients?</atitle><jtitle>Dermatologic therapy</jtitle><addtitle>Dermatol Ther</addtitle><date>2019-11</date><risdate>2019</risdate><volume>32</volume><issue>6</issue><spage>e13115</spage><epage>n/a</epage><pages>e13115-n/a</pages><issn>1396-0296</issn><eissn>1529-8019</eissn><abstract>A 42‐year‐old female with a personal history of Grade II infiltrating ductal breast carcinoma, treated under surgical procedure in 2018, whose hormonal profile included estrogen, progesteronic and HER‐2 positive receptors, and a Ki67 proliferative index (20–25%), was referred to our dermatological outpatient clinic complaining worsening of her chronic spontaneous urticaria. The patient was under treatment with etuximide, exemestane, anastrozole, and trastuzumab. Our patient reported intermittent episodes of hives of 8 years of evolution with good control with second‐generation antihistamines. However, in the past year, the intensity and frequency of the outbreaks was increased with the development of angioedema until completing 23 consultations through the emergency department being treated in all of the episodes with short cycles of oral corticosteroids. This case reported is particularly complex due to different points that we develop below: (a) oncological patient as special population; (b) differential diagnosis with other forms of urticaria such as vasculitis urticaria, inducible urticaria, and autoimmune progesterone dermatitis; (c) spontaneous chronic urticaria of difficult control at labeled dose of omalizumab; (d) concomitant treatment with another biological drug.</abstract><cop>Hoboken, USA</cop><pub>John Wiley &amp; Sons, Inc</pub><pmid>31646716</pmid><doi>10.1111/dth.13115</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0002-5454-3671</orcidid><orcidid>https://orcid.org/0000-0002-0381-6174</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1396-0296
ispartof Dermatologic therapy, 2019-11, Vol.32 (6), p.e13115-n/a
issn 1396-0296
1529-8019
language eng
recordid cdi_proquest_miscellaneous_2308520720
source MEDLINE; Access via Wiley Online Library
subjects Adult
Breast Neoplasms - drug therapy
Carcinoma, Ductal, Breast - drug therapy
Chronic Disease
effectiveness
Female
Humans
omalizumab
Omalizumab - administration & dosage
Omalizumab - adverse effects
safety
trastuzumab
Urticaria - drug therapy
title Is omalizumab safe and effective in oncological patients?
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T11%3A31%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Is%20omalizumab%20safe%20and%20effective%20in%20oncological%20patients?&rft.jtitle=Dermatologic%20therapy&rft.au=Navarro%E2%80%90Trivi%C3%B1o,%20Francisco%20J.&rft.date=2019-11&rft.volume=32&rft.issue=6&rft.spage=e13115&rft.epage=n/a&rft.pages=e13115-n/a&rft.issn=1396-0296&rft.eissn=1529-8019&rft_id=info:doi/10.1111/dth.13115&rft_dat=%3Cproquest_cross%3E2308520720%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2308520720&rft_id=info:pmid/31646716&rfr_iscdi=true